Compare Amplify Cybersecurity ETF (HACK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

HACK trades at $110.08, down 0.86% on the day, with a bullish technical signal driven by moving averages and strong trend momentum (ADX above 60). The ETF benefits from rising cybersecurity spending, which surpassed $300 billion in 2026 (24/7 Wall Street, 2026-07-03), and recently hit a 52-week high (Zacks Investment Research, 2026-05-26). Institutional interest is growing, with D.A. Davidson increasing its stake by 44.8% in Q1 2026 (Defense World, 2026-07-19).

Outlook remains positive due to structural demand for cybersecurity, but risks include sector volatility and reliance on tech spending. The ETF offers exposure to a high-growth theme, yet investors face concentration in tech and sensitivity to corporate budget cycles. Near-term resistance is at $111, with support at $110.

XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.

Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.